A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

July 26, 2018

Study Completion Date

September 5, 2018

Conditions

Colitis, UlcerativeCrohn Disease

Interventions

DRUG

Vedolizumab

Vedolizumab intravenous infusion.

Trial Locations (1)

Peking University First Hospital, Beijing